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Abstract
Recent studies demonstrate that transformation of mild lupus nephritis into end-stage disease is imposed by silencing of
renal DNaseI gene expression in (NZBxNZW)F1 mice. Down-regulation of DNaseI results in reduced chromatin
fragmentation, and in deposition of extracellular chromatin-IgG complexes in glomerular basement membranes in
individuals that produce IgG anti-chromatin antibodies. The main focus of the present study is to describe the biological
consequences of renal DNaseI shut-down and reduced chromatin fragmentation with a particular focus on whether
exposed large chromatin fragments activate Toll like receptors and the necrosis-related Clec4e receptor in murine and
human lupus nephritis. Furthermore, analyses where performed to determine if matrix metalloproteases are up-regulated as
a consequence of chromatin-mediated Toll like receptors/Clec4e stimulation. Mouse and human mRNA expression levels of
DNaseI, Toll like receptors 7–9, Clec4e, pro-inflammatory cytokines and MMP2/MMP9 were determined and compared with
in situ protein expression profiles and clinical data. We demonstrate that exposure of chromatin significantly up-regulate
Toll like receptors and Clec4e in mice, and also but less pronounced in patients with lupus nephritis treated with
immunosuppresants. In conclusion, silencing of renal DNaseI gene expression initiates a cascade of inflammatory signals
leading to progression of both murine and human lupus nephritis. Principal component analyses biplot of data from murine
and human lupus nephrits demonstrate the importance of DNaseI gene shut down for progression of the organ disease.
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Introduction
Lupus nephritis is a serious manifestation of Systemic lupus
erythematosus (SLE) and a major predictor of poor outcome [1,2].
The predominance of chromatin-associated autoantigens involved
in lupus nephritis points at deficiencies in the processing and
clearance of chromatin from dead cells as central factors in the
pathogenesis of SLE [3–8]. Enzymatic DNA fragmentation by
different endonucleases is significant during apoptotic cell death
(reviewed in [9,10]), and in the elimination of chromatin released
from necrotic cells (reviewed in [9–11]). In renal tissue, DNaseI
represents the major endonuclease [12]. A reduced fragmentation
of chromatin during development of nephritis in (NZBxNZW)F1
(BW) mice was shown to coincide with an acquired loss of renal
DNaseI mRNA and enzyme activity [4,5,13]. This appears when
mild mesangial lupus nephritis transforms into end-stage organ
disease [5]. Without adequate degradation by DNaseI, chromatin
may transform into secondary necrotic chromatin released from
apoptotic blebs [7,8,14,15]. In this situation, chromatin fragments
may exert central roles in the pathogenesis of SLE. Chromatin
may activate the innate immune system through interaction with
Toll-like receptors (TLR) 7–9 and the nucleosome-specific
adaptive immune system [16–19]. Next, exposed chromatin may
act as in situ target structures for the induced anti-dsDNA
antibodies (reviewed in [3]).
The chromatin-mediated stimulation of TLR may also up-
regulate certain matrix metalloproteases (MMPs) [20,21]. For
example, engagement of TLRs can up-regulate pro-inflammatory
cytokines (TNFa, IFNc) [22], and Interleukins [23–26] by either
MAPK, ERK kinase or REL through NFkB gene activation
[22,25–28]. Such cytokines can directly up-regulate MMPs
[22,25,26,28,29]. Alternatively, incomplete clearance and degra-
dation of apoptotic cells may transform them into secondary
necrotic cell debris [5,7,30–32]. Necrotic cell debris contains
SAP130, which serves as a ligand for the inflammation-related
receptor Clec4e [33]. Downstream signalling induced by SAP130-
Clec4e interaction also promotes production of pro-inflammatory
cytokines [34,35] and up-regulation of MMPs. Thus, the
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therefore involve TLR [16,36] and the Clec4e receptor [37].
Therefore, it is relevant to include the Clec4e receptor in the
present study, since we hypothesized that loss of renal DNaseI
would result in necrotic transformation of apoptotic cells, with a
consequent release of large chromatin fragments and SAP130
[37,38]. Several studies suggest that TLR signalling is important in
the pathogenesis of lupus nephritis [28,39–42], while the role of
Clec4e in this context is undetermined.
Secreted MMPs have the potential to disintegrate glomerular
basement membranes (GBM) and the mesangial matrix by
enzymatic degradation [43]. This biological event may facilitate
deposition of chromatin fragment-IgG complexes. MMP2/MMP9
activities are reported to be increased within glomeruli of
nephritic, but not pre-nephritic BW mice [5,13,44]. Reduced
expression of renal DNaseI and increased expression of renal
MMPs via the TLR system make a reasonable explanation as to
how large chromatin fragments are generated within the kidneys,
and how they reach access to membranes and matrices.
As a result, we demonstrate that TLR7–9 as well as the Clec4e
receptor and downstream signalling molecules are up-regulated in
untreated lupus prone mice, and most importantly, while less
pronounced, also in human lupus nephritis ISN/RPS class IV,
even though these patients were under treatment. These events
promote up-regulation of renal MMP2 and MMP9, with their
detrimental effects on glomerular matrices and membranes
[28,44,45]. From the present data, we conclude that reduced
renal chromatin metabolism imposed by DNaseI gene silencing is
a key factor to understand how necrotic chromatin-mediated
activation of TLR and Clec4e result in a consequent up-regulation
of pro-inflammatory cytokines, and increased expression of MMP2
and MMP9. These processes will in the end result in deposition of
large chromatin fragments in complex with IgG in GBM, and in
fulminant lupus nephritis [5].
Materials and Methods
Ethic statements
The National Animal Research Authority (NARA) approved
this study (approval ID: 07/11167, ID-178). Coherent analyses on
renal biopsies, taken from patients with lupus nephritis, were
approved by The Scientific Ethical Committee, Copenhagen ((KF)
01-2006-7214). Informed written consent was given by the
patients.
Murine and human renal tissue samples
Renal tissue was collected from female BW mice (Jackson
Laboratory, Bar Harbor, Maine, USA) sacrificed approximately
every second weeks (n=3) from the age of 4 weeks until
development of end-stage disease in the BW mice, clinically
defined when severe proteinuria developed ($20 g/L). Tissue was
either snapfrozen for protein extraction, or preserved in
RNAlaterTM (Qiagen Inc, Valencia, CA, USA) for quantitative
mRNA analyses, or embedded in Tissue Tech OCT compound
for immunofluorescence analyses. Serum samples were collected at
2–3 week intervals and stored at 280uC. Complete sets of murine
data are generated in kidneys from pre-nephritic, antibody
negative (Group 1) BW mice (n=6), BW mice with mesangial
nephritis (Group 2, n=12), and in BW mice with end-stage
membrano-proliferative nephritis (Group 3, n=5). Baseline data
on these mice have been published recently [5]. Renal biopsies
were taken from patients with lupus nephritis. Entry criteria for the
patients were fulfilment of the ACR classification criteria for SLE
[46] and clinical indication for renal biopsy. Control samples from
morphologically normal cortical tissue were sampled from
nephrectomy specimens immediately after the surgical procedure.
Paraffin-embedded tissues from non-lupus renal diseases were
included.
RNA isolation and cDNA synthesis
RNA was isolated from RNAlaterTM preserved human kidney
tissues using TRIzol (Invitrogen, CA,USA) as described by
manufacturer. RNA from murine samples or from human renal
proximal tubule epithelial cells (RPTEC) was isolated from
RNAlaterTM-preserved kidneys using EZ-1 RNA tissue mini kit
(Qiagen, Nordic, Norway) and Qiagen Bio Robot EZ1. The
samples were reverse transcribed with random primers using High
Capacity cDNA Reverse Transcription kit (Applied Biosystems,
Foster City, CA, USA).
TLR signalling Array Assay (n=9 mice) and individual
quantitative PCR analyses (n=23 mice)
Quantitative real time PCR (qPCR) was performed using ABI
Prism 7900HT Sequence Detection System (Applied Biosystems).
RT2 ProfilerTM PCR Array mouse TLR signalling Pathway
array plate (PAMM-018) and the accessory master mix were
purchased from SABiosciences (Frederick, MD, USA). The cDNA
of the respective samples were normalized to a concentration of
1 mg/ml and mixed with the mastermix and used for qPCR.
Relative expression levels were calculated using ddCT method.
Selected sets of data from these array analyses are given in Table 1,
while complete sets of array data are given in Table S1.
Pre-designed FAM-labeled gene expression assays (Applied
Biosystems) were purchased, with the following accession numbers
Table 1. TLR-related signalling: Genes that deviate from
levels in kidneys from Group1 BW mice
&.
Mouse Lupus nephritis Group
Functional
molecules
Affected
genes 1 2 3
Receptors Tlr7 1,8 (61,6) 3,9 (65,7) 9,6 (62,9)
Tlr8 1,5 (61,2) 6,6 (65,2) 29,2 (617,7)*
Tlr9 1,1 (60,4) 2,5 (61,7) 6,2 (62,2)*
Clec4e 1,2 (60,8) 12,9 (616,6) 33,7 (625,3)
Co-stimulatory
molecules
Cd80 1,2 (60,8) 7,1 (64,2) 8,3 (66,6)
CD86 1,1 (60,5) 3,6 (60,2) 5,6 (61,6)**
Signalling molecules
Muc13 1,4 (61,3) 1,8(61,5) 16,7(625,8)
Ly86 1,6 (61,5) 1,7 (61,0) 11,0 (61,9)***
Nfkb2 1,0 (60,3) 1,7 (60,4) 2,7 (60,9)*
Rel 1,1 (60,5) 2,6 (60,1) 3,1 (61,3)*
Myd88 1,1 (60,6) 1,2 (60,2) 2,4 (60,4)
Cytokines/Interleukins
IFNc 1,0 (60,3) 6,2 (63,6) 6,1 (65,6)
TNFa 1,1 (60,4) 4,0 (61,0) 12,4 (610,5)
Il6 1,1 (60,7) 6,8 (68,0) 38,5 (613,6)**
IL-10 1,1 (60,5) 3,9 (62,2) 9,5 (65,4)
&Data are given as fold change (6 SD) compared with gene expression in pre-
nephritic mice.
doi:10.1371/journal.pone.0034080.t001
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Mm01342389_g1, Hs00173736_m1; MMP2 Mm00439506_m1,
Hs00234422_m1; MMP9 Mm00442991_m1, Hs00234579_m1;
TNF a Mm00443258_m1, Hs 00174128_m1; INFc Mm00443258_
m1, Hs 00174128_m1; INFa1 Hs04189288_g1; Clec4e
Mm00490873_m1, Hs00372017_m1; TLR7 Mm00446590_m1 Hs
00152971_mH; TLR8 Mm04209873_m1 Hs 00607866_m1; TLR9
Mm00446193_m1, Hs00928321_m1; b-Actin 4352933E, 4333762F:
Myd88 Hs 00182082_m1; IL-6 Mm01210732_g1, Hs
00985639_m1; IL-10 Mm99999062_m1, Hs 00961622_m1; TBP
4333761F, RPLPO Mm00446973_m1. RPLPO (large ribosomal
protein) was used as endogenous control for human samples and b-
Actin and Tata Box binding protein (TBP) for murine samples. The
relative expression levels were calculated using the ddCT method
relative to pre-nephritic kidneys (for mice) and normal renal tissue (for
human analyses).
Laser capture micro-dissection of murine kidneys
Ten micrometer thick kidney cryosections were prepared and
immediately fixed in zinc buffer (40 mM ZnCl2, 30 mM ZnAc2
and 600 mM CaAc2 in 0.1 M Tris, pH 7.4) for 5 min, stained
with hematoxylin, dehydrated, air-dried, and overlaid with liquid
coverglass (PALMZeiss, Bernreid, Germany). Cortex was collected
by laser capture micro-dissection on a PALM Laser-MicroBeam
System. For each sample, tissue from 10 sections were collected,
lysed in TRIzol (Invitrogen, Carlsbad, CA, USA), and stored at
270uC for further RNA isolation.
Antibodies
Rabbit IgG antibodies specific for mouse and human MMP2
(ab52756), MMP9 (ab73734), TLR7 (ab59921), TLR8 (ab53630),
TLR9 (ab53596) were all from Abcam (Cambridge, UK), while
antibodies against DNase I (sc30058) and Clec4e (SC-161489)
were from Santa Cruz (Santa Cruz Biotechnology, Inc, Santa
Cruz, CA, USA), and antibodies against b-actin (A2066) were
from Sigma-Aldrich (St Louis, MO, USA). Alexa 488-conjugated
F(ab)2 anti-rabbit IgG antibodies were from Invitrogen Life
Technologies (Carlsbad, CA, USA).
Immunofluorescence and immunohistochemistry
analyses
Four micrometer thick sections of OCT-embedded kidneys
were blocked for 30 min in 1% BSA in phosphate-buffered saline
(PBS) followed by washing and 30 min incubation with rabbit
anti-DNaseI, rabbit anti-mouse/human TLR7–9 and goat anti-
Clec4e antibodies. Slides were washed and incubated further for
30 min with Alexa 488-conjugated F(ab)2 anti-rabbit IgG
antibodies. Normal goat and rabbit IgG were used as negative
controls. The sections were analysed by an Olympus BX51
microscope. Immunohistochemical staining was performed as
described [4] and Polink-2 Plus HRP with DAB kit (Newmarket
Scientific, UK) used as detection system.
Cell culture experiments
Human renal proximal tubule epithelial cells (RPTEC) were
purchased from Clontec (Lonza, Switzerland). The cells were
grown in Clontec REGM
TM BulletKit (CC-3190) containing
Renal Epithelial Cell Basal Medium with the following growth
supplements: hEGF, Hydrocortisone, Epinephrine, Insulin, Triio-
dothyronine, Transferrin, GA-1000, and fetal bovine serum at
37uC in 95% humidified air and 5% CO2. The cells were grown to
80% confluence and were activated with TNFa (Sigma-Aldrich,
St. Louis, MO, USA), 0, 15, 30, or 60 ng/ml, or with IFNc
(Sigma-Aldrich), 30, 60, 90, 120 or 240 ng/ml, and the cells were
harvested at 3–6 h for TNFa, and 3–24 h for IFNc, and cellular
expression of MMP2 and MMP9 was analysed by qPCR.
DNaseI Gel Zymography
DNaseI gel zymography was performed exactly as described [5]
using proteins extracted from snap frozen kidney sections from
BW mice.
Western blot
Proteins were extracted from homogenized snap frozen kidneys
(mouse) or frtom the protein phase from the Trizol procedure
(human samples). The protein concentration was determined with
standard BCA assay (ThermoScientific, Oslo, Norway). The
protein concentration was normalized to 0,2 mg/ml and 10 ml
were loaded into Nu PAGE gel (Invitrogen). Electrophoresis and
western blotting were performed according to standard procedures
given by Invitrogen. Membranes were blocked with 5% (w/v)
skimmed milk for 1 h before application of primary antibodies
specific for MMP2, MMP9 and DNaseI overnight at 4uC. Binding
was revealed by chemiluminescence detection. Determination of
molecular weight was done by comparison with MagicMark XP
molecular weight markers (Invitrogen).
ELISA
ELISA kit for mouse MMP9 was obtained from R&D Systems
(Abinodon, UK) and mouse MMP2 from RayBiotech, Inc.
(Norcross GA 30092, USA). The analyses were done according
to the instructions provided by the manufacturers and optical
density was measured spectrophotometrically.
Statistics
Data are presented as mean (6SD). An unpaired t-test was used
to calculate differences of qPCR results in this study excepting
array date where a one-way ANOVA with Dunett post hoc test
was performed; p,0.05 was considered significant. The rcor.test
function from the R language ltm package was used to generate
correlations and significances presented in the square matrix
Table 2, in which all observations were included. Spearman was
used for correlation testing. A principal component analysis (PCA)
was performed on the same set of data and a biplot drawn with the
R biplot function. The PCA biplot is aimed to optimally display
variances and not correlations. In the PCA biplot the direction,
and length of the variable vectors (arrows) give a good indication
as to which variable(s) had the largest influence, positive or
negative, in discriminating the various samples.
Results
TLR7–9 and Clec4e and down-stream signalling are
activated during progression of murine lupus nephritis
Baseline data for the BW mice included in this study has been
published recently [5]. These mice are grouped according to
morphology of the kidneys and presence or absence of serum anti-
dsDNA antibodies: Group 1 mice have no deposits of immune
complexes in the kidneys; Group 2 mice have chromatin-IgG
complex deposits, seen as electron dense structures (EDS, as
described in both murine and human lupus nephritis [6,47]) in the
mesangium; Group 3 mice have EDS in the mesangium and
within the GBM. This separation into 3 groups is in accordance
with the analyses published recently [5,6] (see Figure 1A). Mice
from each group (n=3) were further analysed by a TLR signalling
qPCR array assay on genes linked to the TLR and the Clec4e
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stage of murine lupus nephritis could be systematically divided into
the following subgroups (Table 1): i. Receptors (the TLR7–9 and
Clec4e); ii. Signalling molecules (Myd88, Muc13, Ly86, Nfkb, and
Rel); iii. Co-stimulatory molecules (CD80/CD86); and iv.
cytokines and interleukins (TNFa, IFNc. IL-6, IL-10). Those
Table 2. Correlations and significances.
Age DNase.I EDS.MM* EDS.GBM* Anti-DNA.titer TLR7 TLR8 TLR9 Clec4e MMP2 MMP9 Proteinuria
Age ***** 0,274 0,344 0,353 0,282 0,486 0,475 0,533 0,448 0,081 20,053 0,355
DnaseI 0,206 ***** 0,396 20,391 0,081 20,292 20,189 20,256 20,265 20,227 20,318 20,420
EDS.MM 0,108 0,061 ***** 20,550 0,347 20,194 20,225 20,263 20,370 20,163 20,131 20,475
EDS.GBM 0,099 0,049 0,006 ***** 20,055 0,710 0,766 0,834 0,862 0,339 0,241 0,947
Anti-DNA.titer 0,192 0,715 0,105 0,802 ***** 0,045 0,166 0,393 0,046 0,016 0,347 20,020
TLR7 0,019 0,176 0,376 ,0.001 0,838 ***** 0,534 0,759 0,800 20,075 0,086 0,681
TLR8 0,022 0,388 0,303 ,0.001 0,449 0,009 ***** 0,840 0,611 0,634 0,058 0,749
TLR9 0,009 0,238 0,226 ,0.001 0,064 ,0.001 ,0.001 ***** 0,781 0,302 0,297 0,768
Clec4e 0,032 0,221 0,082 ,0.001 0,835 ,0.001 0,002 ,0.001 ***** 0,092 0,235 0,898
MMP2 0,714 0,297 0,458 0,114 0,941 0,734 0,001 0,162 0,676 ***** 20,031 0,324
MMP9 0,812 0,139 0,552 0,267 0,105 0,697 0,794 0,169 0,280 0,888 ***** 0,202
Proteinuria 0,096 0,046 0,022 ,0.001 0,927 ,0.001 ,0.001 ,0.001 ,0.001 0,131 0,355 *****
*EDS MM and EDS GBM: Electron dense structures in mesangial matrix and in glomerulus basement membranes.
doi:10.1371/journal.pone.0034080.t002
Figure 1. Renal expression of DNaseI, TLR and Clec4e in (NZBxNZW)F1 mice grouped according to glomerular location of EDS. The
mice were sorted into 3 main groups according to kidney morphology (A); pre-nephritic mice (Group 1, no EDS (n=6); mice with mesangial EDS
deposits (Group 2 (n=12)), or mice with EDS in GBM (Group 3 (n=5)). Magnification640 k. In B, mRNA expression levels for renal DNaseI, TLR7–9 and
for the Clec4e receptor with corresponding expression of proteins in kidneys of group 1–3 mice are demonstrated. DNaseI gene expression levels
correlate inversely with TLR7–9 and Clec4e receptor expression levels, both with respect to transcription and translation of the genes in Group 3 of
BW mice. For statistics, see Table 2. Inserts in the DNaseI immunofluorescence panels represent western blots of the DNaseI. An unpaired t-test was
performed (*: p,0,05; ***: p,0,0001).
doi:10.1371/journal.pone.0034080.g001
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complete TLR signalling results are presented in Table S1.
DNaseI gene shut-down correlates with activation of
TLR7–9 and Clec4e
To further explore DNaseI, TLR and Clec4e gene expression in
a larger group of BW mice, individual, selected genes were
analysed by qPCR for Group 1 (n=6), Group 2 (n=12), and in
Group 3 (n=5) BW mice. In Figure 1B, mean values (6SD) for
DNaseI, TLR7–9 and Clec4e mRNA in each mouse group are
presented, and significant differences are indicated by asterisks.
The data demonstrate that DNaseI gene expression was nearby
completely silenced in Group 3 mice, while TLR7–9 and Clec4e
mRNA levels increased significantly during disease progression.
In agreement with the qPCR results, renal expression of the
DNaseI protein in Group 3 mice was undetectable by immuno-
fluorescence and western blot assays compared to staining intensity
in Group1 and Group 2 mice (Figure 1B, western blot results are
inserted in panels in Group 1–3 kidneys). Furthermore, in situ
expression of the TLR7–9 and the Clec4e (Figure 1B) proteins
correlated well with the respective qPCR levels (Figure 1B). Since
Clec4e regulation in lupus nephritis is not determined previously,
we also analysed if this receptor was selectively up-regulated in
nephritic kidneys or in other organs expressing this protein, like
the spleen. Although Clec4e gene expression increased immensely
in kidneys during progression of the disease from mesangial
(Group 2) to membrano-proliferative nephritis (Group 3,
Figure 1B), Clec4e expression levels in spleens remained stable
at baseline levels throughout the disease process (data not shown).
By micro-dissection, and mRNA analyses of renal cortex and
medulla, DNaseI was silenced in both compartments of the
kidneys from Group 3 BW mice, thus demonstrating that DNaseI
gene silencing is not linked to certain renal structures (data not
shown), similar to the DNaseI staining pattern observed by
immunofluorescence analyses of the same kidneys (Figure 1B),
showing a uniform loss of the DNaseI protein.
Silencing of renal DNaseI correlates with exposure of
chromatin, while exposure of chromatin correlates with
TLR7–9 and Clec4e activation
Deposits of large chromatin fragment-IgG complexes in GBM
was observed solely in kidneys of mice from Group 3 with the
lowest renal DNaseI gene expression levels (r=20,39, p,0,05,
Figure 2A), and low DNaseI gene expression also correlated
inversely with severe proteinuria (r=20,42, p,0,05, Figure 2B).
Renal expression of MMPs is thought to be instrumental in
promoting large chromatin-IgG complex deposits in GBM
[5,45,48]. Since MMPs may be imposed by TLR activation
[20,21,49,50], we hypothesized that loss of DNaseI is not directly
correlated with TLR/Clec4e gene activation, but rather indirectly
through reduced fragmentation and a consequent in situ exposure
of secondary necrotic chromatin fragments (for TLRs) and
SAP130 (for Clec4e, [33,51]
In harmony with this assumption, we demonstrate that silencing
of the renal DNaseI gene expression did not directly correlate with
up-regulation of TLR7–9 gene expression (for correlations and
significances, see Figure 2C and Table 2). However, renal
exposure of large undigested chromatin fragments correlated
strongly and significantly with increased TLR7–9 gene expression
(Figure 2D, and Table 2).
Results of analyses of the Clec4e receptor activation strengthen
this observation. As loss of DNaseI did not correlate significantly
with activation of Clec4e (Figure 2E, Table 2), renal exposure of
chromatin fragments correlated highly significantly with increased
expression of Clec4e (Figure 2F, Table 2).
Expression of MMP2 and MMP9 during progressive lupus
TLR activation can directly, or indirectly by increased
expression of TNFa and INFc, up-regulate MMP2 and MMP9
[22,25,26,28,29]. Both TNFa and INFc were found to be up-
regulated inthemurine kidneysduring progression oflupusnephritis
when analyzing all mice in all groups (data not shown), as previously
demonstrated by others [52–56]. Thus, the results demonstrated in
Figures 1 and 2, therefore, may link TLR and Clec4e stimulation
with up-regulation of MMP2 and MMP9, and in cell culture
experiments we observed that TNFa and INFc up-regulated MMP9
and MMP2, respectively, in RPTEC (data not shown).
Data in Figure 3 demonstrate an insignificant increase in renal
MMP2, but not in MMP9 mRNA levels (Figure 3A), and a
corresponding increase in MMP2 protein (western blot, Figure 3B)
or in activated MMP2 (zymography, Figure 3C) in Group 3
kidneys. On the other hand, serum concentrations of MMP2 and
MMP9 were stable in all stages of the disease as demonstrated by
quantitative ELISA for MMP2 and MMP9 (Figure 3D). In
agreement with the hypothesis that MMP2 gene expression is
linked to activation of TLRs, e.g. TLR8 correlates significantly
with expression of MMP2 (r=0,63, p,0,001, Figure 3E).
Expression patterns of DNaseI, TLR7–9, and Clec4e mRNA
and corresponding proteins in kidneys from patients
with lupus nephritis
Human samples are divided into 2 groups according to kidney
morphology; normal controls (n=3) and patients with lupus
nephritis (ISN/RPS class II (n=1) and class IV (n=4) [57]). All
ISN/RPS class IV patients were treated with immunosuppressants
at the time when biopsies were taken (Table 3).
Similar to results obtained in Group 3 BW mice, we observed a
profound silencing of DNaseI gene expression in kidneys with
membrano-proliferative lupus nephritis (ISN/RPS class IV,
Figure 4A) compared with DNaseI mRNA levels in control
kidneys. Very low DNaseI mRNA levels were observed in 3 of the
4, while patients LN4 presented normal DNaseI mRNA level
although having class IV nephritis. However, this patient had been
on treatment continuously the last 11 years (Table 3), which may
have modified the disease process. Western blot analyses of renal
proteins demonstrated a single band corresponding to the MW of
human DNaseI (Figure 4B). Low band intensities were solely
found in the kidney samples that demonstrated considerably
reduced DNaseI mRNA levels (LN 1–3, Figure 4A and 4B).
Similarly, immunohistochemistry analyses of kidney sections
demonstrated strong staining intensity of the DNaseI protein in
normal control kidneys (Figure 4C) and in ISN/RPS class II
kidneys (Figure 4C). In ISN/RPS class IV kidneys, DNaseI
staining of LN 1–3 was barely detectable (Figure 4C), in
agreement with the low DNaseI mRNA levels in these patients.
Proteins from kidneys of LN4 were not available for this analysis.
Control analyses in other renal diseases (like diabetic nephroscle-
rosis or membrano-proliferative glomerulonephritis type 2)
demonstrated DNaseI staining intensity similar to that in normal
kidneys, and kidneys with ISN/RPS class II lupus nephritis
(Figure 4C). Taken together, shut-down of the renal DNaseI gene
expression seems to be an event linked to progression of both
murine and human lupus nephritis, as has been indicated in a
previous pilot study [13]. Thus, DNaseI shut down in progressive
lupus nephritis is not a general phenomenon linked to e.g. renal
inflammation.
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regulated in class IV nephritis, although without reaching
statistical significance (Figure 4D). The TLR 9 and Clec4e mRNA
levels did not differ at all from the control group (data not shown).
In harmony with this, immunohistochemical staining of kidneys
with class IV lupus nephritis revealed increased staining intensity
of TLR8 (see Figure 4E for details on each TLR). The discrepancy
of TLR expression between murine and human nephritis may be
due the fact that these patients had been treated with
immunosuppressive drugs while mice were not. The LN6, having
mesangial lupus nephritis ISN/RPS class II, had normal levels of
DNaseI, TLR7–9 and Clec4e mRNA levels (data not shown),
similar to BW mice with mesangial nephritis.
Expression patterns of MMP2 and MMP9 in kidneys from
patients with human ISN/RPS class IV lupus nephritis
As demonstrated in Figure 5A, the MMP2 and MMP9 mRNA
levels were significantly up-regulated in class IV lupus nephritis.
The high MMP2 and MMP9 mRNA levels were also reflected by
increased protein levels as demonstrated by western blots
(Figure 5B) and by immunohistochemistry (Figure 5C), thus
demonstrating that these proteins are strongly expressed in class
IV kidneys.
Overall statistical and PCA biplot analyses of the data
obtained in this study
Table 2 shows a square matrix where the upper diagonal part
demonstrates Spearman correlation coefficients. The lower
diagonal part presents the corresponding p-values for all murine
data included in this study. In Figure 6, the result of a principal
component analysis (PCA) biplot drawn with the R biplot function
is demonstrated. The PCA biplot is aimed to optimally display
variances and not correlations. The angles between the various
biplot axes are good indicators of the correlations among the
variables (shown as arrows). In A, the murine, and in B the human
biplot on LN 1–3, and in C the human biplot for LN 1–4 are
presented. In B and C the biplot varies since in B all data are from
the 3 kidneys with low DNaseI, while in C, the vectors is shown to
differ due to the fact that one patient (LN4) had normal renal
DNaseI. The result of the murine PCA biplot (Figure 6A)
demonstrate that the mice confine perfectly into three groups, one
pre-nephritic (Group 1, all mice labelled with 1), one with mild
Figure 2. Silencing of renal DNaseI correlates with chromatin deposition in GBM and severe proteinuria, while exposure of
chromatin correlates significantly with activation of TLR7–9 and Clec4e. Reduced expression of renal DNaseI correlates inversely with
chromatin-IgG deposits in GBM (A) and with severe proteinuria (B). TLR7–9 activation is not significantly correlated with silenced renal DNaseI (C),
while a consequence of reduced DNaseI enzyme activity, i.e. exposure of chromatin in e.g. GBM demonstrate a strong and highly significant
correlation with TLR7–9 activation (D). ). Similarly, the Clec4e receptor activation is not significantly correlated with silenced renal DNaseI (E), while
exposure of secondary necrotic chromatin demonstrate a strong and highly significant positive correlation with Clec4e activation (F).
doi:10.1371/journal.pone.0034080.g002
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end-stage membrano-proliferative nephritis (Group 3, mice
labelled with 3). This result confirms that the parameters used to
group BW mice as in Figure 1A are biologically relevant. In sum,
the data demonstrate a highly significant inverted correlation
between proteinuria/EDS in GBM and DNaseI gene expression,
while EDS in GBM was significantly associated with activation of
TLR7–9 and clec4e (Table 2).
Similarly, the position of individual human controls (ctr1–3) and
patients (LN1–3 (B)) or (LN1–4 (C)) relative to the vectors provides
good indications as to which variable(s) have had the largest effect
in each individual patient. As is evident in data presented in
Figure 6, the DNaseI vector points towards normal murine
(Group1) and human (ctr 1–3) individuals due to its inverse impact
on disease progression.
The data presented in Table 2 and in Figure 6A–C are relevant
to explain biological events imposed by the DNaseI shut-down and
its role for progression of lupus nephritis. In sum, the vector that
point at chromatin-IgG deposits in GBM are clustered with
vectors pointing at TLR7–9, Clec4e, MMP2 and MMP9,
indicating an interdependency between them, while the DNaseI
vector points the opposite direction due to its negative correlation
with advanced lupus nephritis.
Discussion
At a certain time point in the life of BW mice, the renal DNaseI
mRNA and enzyme activity is inevitably lost. Acquired silencing of
renal DNaseI gene expression appears to have an immense
pathogenic impact on progressive lupus nephritis [4,5,13,58]. The
clinical consequence of renal DNaseI gene silencing is an
inevitable transformation of mild mesangial lupus nephritis into
end-stage organ disease. In this respect, two questions are regarded
important to answer; i. why the renal DNaseI gene is silenced
(studies in progress); and ii. if loss of DNaseI activity is the event
that imposes increased MMP activity through interaction of un-
fragmented secondary necrotic chromatin with TLRs and the
Clec4e receptor (present study).
However, exposure of chromatin may not by itself be sufficient
to impose clinical lupus nephritis. For example, similar in situ
exposure and retention of large un-fragmented chromatin
fragments have been described in several experimental nuclease
deficiencies on non-autoimmune backgrounds (see e.g. [9,59–61]).
The clinical consequence of chromatin fragments in these
experimental nuclease deficiencies differ from that in kidneys of
individuals with lupus nephritis, simply because in the latter,
antibodies to chromatin are present. Thus, antibodies to dsDNA
may be the factors that render exposed chromatin pathogenic.
In this study we analysed the pathophysiological effect of renal
exposure of chromatin fragments. The basic hypothesis was that
exposure of chromatin may be the factor that indirectly up-
regulate expression of MMPs. This up-regulation may be induced
by at least 3 different pathways: i. directly through interaction of
chromatin with TLR [20,21,49]; ii. indirectly through TLR -
mediated up-regulation of TNFa and IFNc, both having the
capacity to induce increased expression of MMP2/MMP9 enzyme
activity [23–25]; or iii. indirectly through downstream signalling
induced by interaction between debris released from apoptotic and
secondary necrotic cells [30,62] and the Clec4e receptor, and a
consequent up-regulation of proinflammatory cytokines [34,35].
The three pathways indicated above are all operational in up-
regulation of MMP2, and to a lesser extent MMP9, and may
actually be co-operative in lupus nephritis. Thus, it may be true
that MMPs represent the factor that disintegrate membranes in
progressive lupus nephritis and thereby provide access in situ for
large chromatin fragments that have escaped DNaseI-mediated
fragmentation.
A more detailed pathophysiological picture of lupus nephritis
appears from data described here, and previously [5]. The process
resulting in fulminant lupus nephritis may be summarized as
follows. Appearance of anti-dsDNA antibodies, followed by
formation of small chromatin fragment-IgG complexes and their
Figure 3. Expression of the MMP2 and MMP9 in kidneys of BW mice. Data demonstrate an insignificant increase in renal MMP2, but not in
MMP9 mRNA levels in Group 3 mice compared with mice from Group 1 and 2 (A), and a corresponding increase in MMP2 protein (western blot, B) or
in activated MMP2 (zymography, C). Serum concentrations of MMP2 and MMP9 were stable in all stages of the disease as demonstrated by
quantitative ELISA for MMP2 and MMP9 (Figure 3D). In agreement with the hypothesis that MMP2 gene expression is linked to activation of TLRs,
TLR8 correlates significantly with expression of MMP2 (r=0,63, p,0,001, E).
doi:10.1371/journal.pone.0034080.g003
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Patient
ID
Gender/age
(years) ACR criteria
a
Disease
duration
ISN/RPS class
lupus nephritis
Activity/Chronicity
score
Anti-dsDNA
antibody
s-Creatinin
(mmol/L)
Proteinuria
(g/24 h) Therapy
LN1 R/39 1,4,5,7,9,10,11 2 months IV 6/1 400 (cut-off 15) 78 2.4 Prednisolone
H-Chlorochine
LN2 R/18 5,7,10,11 6 weeks IV 7/1 .400 (cut-off 15) 68 3.6 Prednisolone
LN3 =/22 1,4,7,9,10,11 3.5 years IV 9/10 .400 (cut-off 15) 357 9.0 Prednisolone
Mycophenolate
LN4 R/32 5,7,9,10,11 11 years IV 6/2 .400 (cut-off 15) 66 1.0 Prednisolone
LN6 R/40 4,6,7,9,10,11 11 months I 0/3 153 (cut-off 35) 57 2.0 None
aACR-criteria: 1=malar rash, 2=discoid rash, 3=photosensitivity, 4=oral ulcers, 5=arthritis, 6=serositis, 7=renal disorder, 9=hematologic disorder, 10=immunologic
disorder: Anti-dsDNA, anti-Sm, and/or anti-phospholipid antibodies, 11=ANA.
doi:10.1371/journal.pone.0034080.t003
Figure 4. Expression patterns of DNaseI, TLR7–9 in kidneys from patients with lupus nephritis. A profound silencing of DNaseI gene
expression in kidneys with membranoproliferative lupus nephritis (ISN/RPS class IV, A) compared with DNaseI mRNA levels in control kidneys.
Western blot analyses of renal proteins demonstrated a single band corresponding to the MW of human DNaseI (B). Low band intensities were solely
found in the kidney samples that demonstrated considerably reduced DNaseI mRNA levels (LN 1–3, A and B). Similarly, immunohistochemistry
analyses of kidney sections demonstrated strong staining intensity of the DNaseI protein in normal control kidneys (C) and in ISN/RPS class II kidneys
(C). In ISN/RPS class IV kidneys, DNaseI staining was barely detectable (C), in agreement with the low DNaseI mRNA levels in these patients. Control
analyses in other renal diseases (like diabetic nephrosclerosis or membranoproliferative glomerulonephritis type 2) demonstrated DNaseI staining
intensity similar to that in normal kidneys, and kidneys with ISN/RPS class II lupus nephritis (C). The qPCR analyses revealed that TLR7 and TLR 8 were
up-regulated in class IV nephritis, although without reaching statistical significance (D). The TLR 9 and Clec4e (data not shown) mRNA levels did not
differ at all from the control group. In harmony with this, immunohistochemical staining of kidneys with class IV lupus nephritis revealed increased
staining intensity of TLR8 (E). An unpaired t-test is performed (*p,0,05).
doi:10.1371/journal.pone.0034080.g004
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induce mild or silent mesangial nephritis [5,13]. The inflammatory
milieu created by the early mesangial nephritis process may,
although it deceptively appears as a clinically non-significant
disorder, be the factors that silence the DNaseI gene expression.
This model may be valid both for focal nephritis, and for global
end-stage nephritis, depending on whether DNaseI is silenced
globally in the kidney or only in smaller inflammation affected
renal foci. The latter is currently under investigation in our
laboratory. Thus, data presented here may point at early, clinically
silent or mild mesangial nephritis as an inducer of DNaseI
silencing. This indicates a wider effect on the genomic region and
further epigenetic analyses are needed to explain this latter
phenomenon.
Contemporary studies are consequently focused to identify the
epigenetical mechanisms that account for silencing of the DNaseI
gene. We are currently analysing two mechanisms; i. the role of
regulatory RNAs, and have yet identified at least one microRNA
in murine lupus nephritis that theoretically target DNaseI mRNA;
and ii. transcriptional interference with closely situated genes. Of
importance is also to identify the timely relationship between
inducers of DNaseI gene silencing, and if the silencing is the direct
cause for progression of lupus nephritis from mild mesangial
nephritis into end-stage organ disease. This process may be
relevant to understand the basis for focal as well as global lupus
nephritis. In renal regions where DNaseI activity is low, un-
fragmented chromatin may be retained and bound to membranes
and targeted by relevant potentially nephritogenic anti-chromatin
autoantibodies. Thus, focal lupus nephritis (see [63] for classifica-
tion of lupus nephritis) may reflect focal glomerular exposure of
chromatin fragments that have escaped degradation in regions
with silenced DNaseI gene. If silencing of DNaseI appears globally
in the kidneys of a given patient, this will promote a uniform end-
stage disease.
To understand how the DNaseI gene is down-regulated in the
kidney may bring us a significant step towards the understanding
of the molecular and genetical events that in the end result in
progressive lupus nephritis. This insight may also be important to
develop new and causal treatment strategies, like inhibiting
DNaseI gene silencing, or to inhibit binding of chromatin to
membranes along strategies recently published [64].
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Array mouse TLR signalling Pathway array plate (PAMM-018) is
Figure 5. Expression of MMP2 and MMP9 in kidneys from patients with human ISN/RPS class IV lupus nephritis. The MMP2 and MMP9
mRNA levels were significantly up-regulated in class IV lupus nephritis compared with control kidneys (A). The high MMP2 and MMP9 mRNA levels
were also reflected by increased protein levels as demonstrated by western blots (B) and by immunohistochemistry (C). Taken together, MMP2 and
MMP9 mRNA and protein levels are highly expressed in human class IV lupus nephritis. An unpaired t-test is performed (*p,0,05).
doi:10.1371/journal.pone.0034080.g005
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Group 1 mice (set to 1). Relative expression levels were calculated
using ddCT method. Selected sets of data from these array
analyses are given in Table 1.
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